2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. Carbonic Anhydrase Isoform

Carbonic Anhydrase

 

Carbonic Anhydrase Related Products (99):

Cat. No. Product Name Effect Purity
  • HY-13650
    Indisulam
    		Inhibitor 99.60%
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
  • HY-B1480
    Ethoxzolamide
    		Inhibitor 99.43%
    Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
  • HY-N0639
    Punicalin
    		Inhibitor 99.89%
    Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.
  • HY-B0122
    Topiramate
    		Inhibitor ≥98.0%
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
  • HY-B0588
    Brinzolamide
    		Inhibitor 99.61%
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
  • HY-163109
    Carbonic anhydrase inhibitor 16
    		Inhibitor 98.00%
    Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (Ki: 28.5 nM, 2.2 nM).
  • HY-161174
    Carbonic anhydrase inhibitor 17
    		Inhibitor
    Carbonic anhydrase inhibitor 17 (compound 7c) ,pyridazine-tethered sulfonamide, is a carbonic anhydrase II inhibitor with IC50 of 0.63 nM.
  • HY-B0588R
    Brinzolamide (Standard)
    		Inhibitor
    Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
  • HY-B0782A
    Acetazolamide sodium
    		Inhibitor 99.66%
    Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.
  • HY-B0397
    Dichlorphenamide
    		Inhibitor 98.90%
    Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.
  • HY-110243
    CAIX Inhibitor S4
    		Inhibitor 98.90%
    CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth.
  • HY-P1775
    Carbonic anhydrase, Bovine erythrocytes
    Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.
  • HY-B0483
    Tioxolone
    		Inhibitor 98.24%
    Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
  • HY-118467
    Benzolamide
    		Inhibitor 98.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
  • HY-N0085
    Dimethylfraxetin
    		Inhibitor 99.97%
    Dimethylfraxetin is a Carbonic anhydrase inhibitor, with a Ki value of 0.0097 μM.
  • HY-B0562
    Methyclothiazide
    		99.76%
    Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro.
  • HY-108316
    Sultiame
    		Inhibitor 99.76%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
  • HY-148135
    hCAI/II-IN-6
    		Inhibitor ≥98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
  • HY-B0782S
    Acetazolamide-d3
    		Inhibitor 99.95%
    Acetazolamide-d3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.
  • HY-B0109
    Dorzolamide
    		Inhibitor
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.